Bo Qi

Bo Qi has is responsible for China CMC development, operations and manufacturing. He has 28+ years of experience focused on process development, characterization, validation, and commercial manufacturing operations, throughout the biologic drug lifecycle from IND to BLA and commercial launch.

Previously, Bo Qi was the Director of CMC Development, Eli Lilly; in charge of process development (PD), PD analytical and pilot plant production and directly contributed to the commercial launch of 3 oncology monoclonal antibodies.

Prior to Eli Lilly, Director of Process Development, ImClone Systems; established the process characterization and validation platforms and contributed to the commercial launch of Erbitux.

Bo Qi earned an MSc in Biochemistry from the University of Minnesota.